A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05145413 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Xanomeline and Trospium Chloride Capsules
DRUG: Placebo

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company